Discovery & overview
Ipamorelin came out of a chemistry programme.
The peptide that released growth hormone and nothing else
Ipamorelin came out of a chemistry programme. Researchers at Novo Nordisk first synthesized it in the mid-1990s, working from the older growth-hormone-releasing peptide GHRP-1, and the pentapeptide they published in 1998 released a clean GH pulse without the ACTH and cortisol rise the earlier compounds produced, in swine. The authors called that result very surprising, so read the selectivity as a finding rather than a design brief. Note the boundary of the claim: that paper reports a hormone panel in animals and nothing on appetite, and later mouse work found that GH secretagogues as a class, ipamorelin among them, raised food intake and serum leptin, while ipamorelin itself added a small 15% increase in body weight by two weeks.
This unit traces that lineage, defines the vocabulary you will need, and sets the honest evidence picture up front: a strong mechanism, one clean Phase I study, a published Phase II trial that failed its main goal, a second and larger Phase II that has posted no results, and no FDA-approved product containing it.
What you'll learn
- What ipamorelin is and how its selectivity was found
- How the GH axis and the GHSR receptor actually work
- How to read the CJC-1295 stack claim honestly
- How to read the evidence honestly, including the failed trial
- Where ipamorelin stands legally and in anti-doping
What this course covers
11 units take you from the essentials to an in-depth understanding.
- 01 Discovery & overview The peptide that released growth hormone and nothing else free
- 02 The GH axis & GHSR The control system ipamorelin plugs into paid
- 03 Chemistry & structure A small, deliberately sturdy molecule paid
- 04 The selective mechanism What "selective" really means here paid
- 05 The CJC-1295 stack Why ipamorelin is almost always paired paid
- 06 The clinical evidence What the human and animal studies actually found paid
- 07 Applications & claims What people use it for, and what holds up paid
- 08 Safety & side effects What we know about safety, and the large gaps paid
- 09 Dosing & Administration How it is prepared and used, for education only paid
- 10 Regulatory landscape No FDA approval, and outside US compounding paid
- 11 Final Exam & Certification Pass the final exam to earn your certificate of completion. Exam
Key terms
Where ipamorelin came from
The story starts with Cyril Bowers, whose 1984 report showed that a small synthetic hexapeptide could release growth hormone on its own, in rats, monkeys, lambs and calves, without a concomitant release of LH, FSH, TSH or prolactin. A 2018 review of the class names that hexapeptide, now known as GHRP-6, the first growth-hormone-releasing peptide with significant activity in living animals, and ipamorelin was later found in a chemistry series built on a related peptide, GHRP-1.
The earlier GHRPs worked, but they were noisy. In normal men, the top dose of the prototype hexapeptide pushed both prolactin and cortisol up about two-fold above basal levels, and in mice this class raised food intake and body fat. Ipamorelin is still discussed because, in the 1998 swine work, it kept the growth-hormone effect without that ACTH and cortisol rise, a result its own authors called very surprising.
AdvancedWhy the receptor came before the natural hormone
Unusually, the receptor (GHS-R1a) was identified in 1996, three years before its natural activator ghrelin was found in 1999. For a while scientists had a target with no known endogenous key, which is part of why synthetic peptides like the GHRPs drove this whole field.
The family it belongs to
Ipamorelin is one member of a small family of growth-hormone secretagogues. They share a target but differ sharply in how clean their effect is, and that difference is what ipamorelin became known for.
Notice the pattern: every compound hits the same receptor, but in the swine comparison the older ones spilled over into the stress-hormone axis, raising plasma ACTH and cortisol. Ipamorelin’s claim to fame is not that it releases more GH, it is that it released GH more cleanly than its predecessors in that experiment.
AdvancedWhat made the design different
FDA’s review describes ipamorelin as identified in 1998 from a series of compounds lacking the central Ala-Trp dipeptide of GHRP-1, and the chain it ended up with opens on the non-natural residue Aib. It is often said that this substitution is what buys the selectivity, but no source in this course’s bibliography tests that attribution.
What ipamorelin actually is
Strip away the marketing and ipamorelin is a short chain of five amino acids, Aib-His-D-2-Nal-D-Phe-Lys-NH2. Three of the five are non-standard: FDA’s review notes that Aib and naphthylalanine (Nal) are not among the amino acids the body builds proteins from, and D-Phe is the mirror-image form of a natural one. The NH2 at the end marks an amide cap on the tail.
Because it works through your own pituitary, ipamorelin is not the same thing as injecting growth hormone. It produces a pulse of your own GH, and that pulse fades within a few hours. This is the single most important idea to carry into the rest of the course.
AdvancedWhy two of the residues are mirror images
D-amino acids are the mirror image of the natural L-form, and ipamorelin carries two of them, D-2-Nal and D-Phe. In general peptide chemistry, enzymes shaped to cut L-residues handle D-residues poorly, which is the usual reason for building them in. Read that as general chemistry: the cited papers report potency for ipamorelin and the analogs built from it, and none of them tests what these two D-residues contribute to its stability or selectivity.
The honest evidence ceiling
Before the deeper science, the honest picture. The mechanism and the short-term pharmacology are genuinely well-characterized. The clinical outcomes that people actually want, fat loss, anti-aging, recovery, have no controlled human trial of ipamorelin in any source this course cites; the one published efficacy trial tested gut function after bowel surgery, and it was negative.
The gap between those tiers is the point of this whole course. The mechanism is real and the short-term pharmacology is clean, but the popular benefit claims sit on the weak and missing tiers. Keeping the solid science separate from the wishful extrapolation is the skill to carry forward.
This course is education, not medical advice. No FDA-approved product contains ipamorelin, and nothing here is a recommendation to use it.
Popular claims, checked
A handful of claims you will see online, held against the actual evidence. The recurring problem is not that the claims are absurd, it is that mechanism-level plausibility gets sold as if it were a proven clinical outcome.
Reading each claim against its real evidence tier is the core skill this course builds. The selective-GH-release claim is solid; the clinical-benefit claims are extrapolation. Keeping those two apart is what separates education from a sales pitch.
AdvancedWhy "your own GH" matters
Injecting HGH raises growth hormone to a sustained, externally set level. Ipamorelin instead asks the pituitary for a brief pulse: the human study saw a single episode of release declining to negligible levels. A 2018 review of the class says these peptides release GH without affecting the axis’s normal negative feedback through somatostatin and IGF-1, which is the usual argument for calling this a gentler stimulus. Hold that as a statement about the class rather than an ipamorelin measurement: the human study’s abstract reports ipamorelin and GH concentrations, not feedback. Either way it cannot deliver the dose control of true GH therapy.
Where it sits among the options
Ipamorelin is rarely discussed alone. It lives in a landscape of GH-axis compounds, and understanding the neighbors makes its strengths and gaps obvious, especially the one neighbor that actually has an approved body-composition label.
The honest framing is that tesamorelin, not ipamorelin, holds the only approved GH-axis body-composition label in this course’s sources, and even that is narrow. Ipamorelin’s appeal is its clean mechanism and the story told about the CJC-1295 stack, not a track record of measured outcomes.